Lactocore CEO On Peptide-Based Drug Candidates For Anxiety, Obesity, Parkinson’s And More

US-based biotech Lactocore Group’s CEO and co-founder Anton Malyshev talks to Scrip on milk-derived, novel peptides that hold potential as safe and effective treatments for a range of common psychiatric, metabolic and cognitive disorders. Lead asset LCGA-17 with indications for mental health conditions, like anxiety and post-traumatic stress disorder, is at the pre-Investigational New Drug stage and could have the unique advantage of intranasal administration. Another asset can regulate appetite, with potential to treat obesity and type-2 diabetes and a third could find use as adjunct or complimentary therapy for Parkinson’s disease.